Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC)
Sandler, Howard M., Freedland, Stephen J., Shore, Neal D., Smith, Matthew Raymond, Rosales, Rosamerlinda S., Brookman-May, Sabine D., Dearnaley, David P., Dicker, Adam P., McKenzie, Michael R., Bossi, Alberto, Widmark, Anders, Wiegel, Thomas, Martin, Jason L., Miladinovic, Branko, Whalen, Jennifer Anne, Ciprotti, Marika, McCarthy, Sharon, Mundle, Suneel, Tombal, Bertrand F., Feng, Felix Y
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article